Redifferentiation therapy with selpercatinib in RET-fusion-positive advanced thyroid carcinoma: a case report and literature review
Frontiers in Oncology · 29.06.2026 · 16
DOI: 10.3389/fonc.2026.1819030 ↗Kurz gefasst
Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 29.06.2026. Verfasst von Edoardo Talpacci und 6 weiteren Autor:innen. Beteiligte Einrichtung: Section of Internal Medicine and Endocrine and Metabolic Sciences, Department of Medicine and Surgery, University of Perugia, Perugia, Italy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Radioiodine-refractory differentiated thyroid carcinoma (RAI-R-DTC) represents a major therapeutic challenge, and strategies aimed at restoring iodine avidity are of increasing clinical interest. We report the case of a 58 year old woman with metastatic papillary thyroid carcinoma harboring a CCDC6:RET fusion, who developed progressive RAI-refractory disease decades after initial surgery and multiple 131 I-treatments. After a first-line cycle with Lenvatinib characterized by limited efficacy and poor tolerability, a second-line therapy with the selective RET inhibitor Selpercatinib was initiated, resulting in a sustained partial radiological response. Notably, after 17 months of treatment, a diagnostic 131 I whole-body scan following rhTSH stimulation demonstrated radioiodine uptake restoration in distant metastases, enabling successful retreatment with 131 I. This was followed by a marked biochemical response and further reduction in tumor burden, with durable disease control under combined therapy. This case illustrates Selpercatinib-induced redifferentiation in RET fusion–positive RAI-R-DTC and supports the emerging role of genotype-driven targeted therapies to restore radioiodine sensitivity. A review of the available literature underscores the potential of selective RET inhibition as a redifferentiation strategy, although further prospective studies are needed to define optimal patient selection and treatment sequencing.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Section of Internal Medicine and Endocrine and Metabolic Sciences, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
- Department of Diagnostic Imaging, Nuclear Medicine Unit, Perugia General Hospital, Perugia, Italy.
Zitieren
APA
Talpacci, E., Morelli, S., Ingriccini, C., Ferrieri, A., Tranfaglia, C., Dottorini, M. E., & Puxeddu, E. (2026). Redifferentiation therapy with selpercatinib in RET-fusion-positive advanced thyroid carcinoma: a case report and literature review. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1819030
Vancouver
Talpacci E, Morelli S, Ingriccini C, Ferrieri A, Tranfaglia C, Dottorini ME, et al. Redifferentiation therapy with selpercatinib in RET-fusion-positive advanced thyroid carcinoma: a case report and literature review. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1819030
BibTeX
@article{Talpacci2026,
author = {Talpacci, Edoardo and Morelli, Silvia and Ingriccini, Chiara and Ferrieri, Antonella and Tranfaglia, Cristina and Dottorini, Massimo Eugenio and Puxeddu, Efisio},
title = {Redifferentiation therapy with selpercatinib in RET-fusion-positive advanced thyroid carcinoma: a case report and literature review},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1819030}
}
EUVIMED